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Risk assessment of deoxynivalenol 
in high-risk area of China by human 
biomonitoring using an improved 
high throughput UPLC-MS/MS 
method
Chunli Deng1, Chenglong Li1, Shuang Zhou1, Xiaodan Wang1, Haibin Xu1, Dan Wang1,  
Yun Yun Gong1,2, Michael N. Routledge3, Yunfeng Zhao1 & Yongning Wu1
A risk assessment of deoxynivalenol (DON) was recently conducted for the residents in Henan province, 
China, where wheat as the staple food are highly consumed. A high-throughput sensitive UPLC-MS/
MS method following 96-well μElution solid-phase extraction (SPE) were developed and validated for 
the determination of DON biomarkers in human urine. Isotope labelled internal standard, 13C-DON, 
was used for accurate quantification. Urinary samples collected from 151 healthy Chinese aged 2–78 
years were processed with and without enzyme hydrolysis to determine total and free biomarkers, 
respectively. DON, and de-epoxy-deoxynivalenol (DOM-1) to a lesser extent, can be frequently 
detected in these samples both with and without enzyme hydrolysis. Free DOM-1 was detected at low 
level in human urine for the first time. Total DON was detected in all samples with a mean concentration 
at 47.6 ng mL−1. The mean and median probable daily intakes (PDI) for the whole participants, 
estimated to be 1.61 μg/kg bw and 1.10 μg/kg bw, both exceeded the PMTDI (1 μg/kg bw/day), 
indicating a potential risk for the residents in this area, especially for children and adolescents.
Deoxynivalenol (DON), belonging to the trichothecenes group produced by Fusarium spp. is one of the most 
prevalent mycotoxins1. Various crops are easily infested by these molds and thereby contaminated with DON, 
which is responsible for gastro-intestinal problems in humans as well as other potential adverse effects on human 
health, including immunosuppression and impairment of reproduction and development2. In response, the Joint 
FAO/WHO Expert Committee on Food Additives (JECFA) conducted a series of risk assessments and established 
a provisional maximum tolerable daily intake (PMTDI) of 1 μg/kg bw/day for the total amount of DON and its 
acetylated derivatives, 3-acetyl-deoxynivalenol (3ADON) and 15-acetyl-deoxynivalenol (15ADON)3. This led to 
many countries setting maximum permitted levels for DON4.
After ingestion, DON undergoes a rapid metabolization to DON-glucuronide conjugates, mainly DON-
3-glucuronide (D-3-GlcA) and deoxynivalenol-15-glucuronide (D-15-GlcA)5. Additionally, a small proportion 
of DON can be detoxified to DOM-1 by gut microbiota, which can also conjugate with glucuronic acid and be 
excreted in the urine6.
Humans and animals are exposed to DON by ingestion of contaminated food1. Assessment of human expo-
sure to mycotoxins is conventionally performed by analysis of food contamination levels and calculation of intake 
based on consumption data7–9. The heterogeneous distribution of mycotoxins in food may affect the accuracy of 
these results, whereas a biomarkers-based strategy can provide a less biased measure of mycotoxin intake.
A strong correlation has been demonstrated between the total DON (free DON together with 
DON-glucuronides) in urine and dietary DON intake in several studies5,10,11. DON biomarker analysis was initi-
ated by Meky et al., via the measurement of total DON after enzymatic deconjugation12 and further improved by 
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inclusion of isotope internal standard correction13. Subsequently, a number of approaches for the determination 
of DON biomarkers have been proposed for biological samples, involving gas chromatography-mass spectrom-
etry (GC-MS)14–17, liquid chromatography-mass spectrometry (LC-MS)13,18–20, liquid chromatography-tandem 
mass spectrometry (LC-MS/MS)6,21–24, and other rapid screening methods such as Fourier-Transform Infrared 
Spectrometry25, fluorescence excitation-emission matrix26, and enzyme-linked immunosorbent assay (ELISA)27. 
Among them, LC-MS/MS provides excellent accuracy, sensitivity and selectivity, and has become a preferred 
technique. Most of these studies focused only on DON, DOM-1 and their glucuronides. DON acetylated deriva-
tives (3-A-DON and 15-A-DON), also known as masked DON28, were commonly not included in the biological 
sample analysis, since these compounds could be digested to release DON in vivo. In these assays, solid-phase 
extraction (SPE) and immunoaffinity columns have been widely used for sample preparation, effectively reducing 
matrix interference and achieving a high increase in sensitivity. However, the labor-intensive and time-consuming 
steps of these conventional approaches present challenges to their further application in large-scale analysis.
To address such issues, we have developed a high-throughput UPLC-MS/MS method involving a 96-well 
μElution plate for the determination of total and free DON and DOM-1 in urine. This is the first application of 
μElution plate for DON biomarker analysis, which enables the simultaneous preparation of multiple samples 
without evaporation and reconstitution steps. Using this method, 151 urine samples collected from healthy vol-
unteers in Henan province, China were evaluated for DON exposure.
Results
Method development and validation. MS/MS conditions were optimized manually by individual 
infusions of each analyte standard. The detailed parameters for each analyte were optimized as summarized in 
Table 1. Waters CORTECS C18 UPLC column (2.1 mm × 100 mm, 1.6 μm) with methanol and water as mobile 
phase under a gradient elution provided a complete separation of the analytes as well as their analogs for a sin-
gle run, as displayed in Fig. 1. It is noteworthy that formic acid and ammonium formate used as mobile phase 
additives resulted in a strong suppression of ionization and thereby worse signal intensity of DON and DOM-
1. A high-throughput sample preparation strategy implementing a 96-well Oasis® PRiME HLB μElution Plate 
was used for DON biomarker analysis. To improve recovery and selectivity, the detailed parameters associ-
ated with loading, washing and elution buffer as well as the enzymatic hydrolysis process were optimized (see 
Supplementary Information, Table S1 and Figure S1). To our best knowledge, this is the first report that enables 
high-throughput analysis for DON biomarkers, allowing 96 urine samples (one plate) to be processed within 2 h 
with good extraction recoveries (88.3~112%) and well-controlled matrix interference (67.4~83.2%).
Method validation was carried out as described in the Method section, following the recommendations of 
EMEA29 and US FDA30. The LOD and LOQ were 0.5 ng mL−1 and 1 ng mL−1, respectively for DON. For DOM-1, 
Analyte
Parent ion 
(m/z)
Daughter 
ion (m/z)
Cone 
voltage (V)
Collision 
energy (eV)
DON 297.2
231.2 +36 +10
249.2a +36 +8
13C-DON 312.2
245.1 +20 +10
263.2a +20 +8
DOM-1 281.2
109.1 +26 +14
233.2a +26 +8
Table 1. MRM transitions of the analytes. aTransition used for quantification.
Figure 1. Extracted ion chromatograms based on MRM transitions for DON, DOM-1 and their major analogs 
(5 ng mL−1 of each compound).
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the LOD and LOQ were 0.1 ng mL−1 and 0.2 ng mL−1, respectively (Table 2). All analytes showed good linearity 
from their respective LOQ up to 100 ng mL−1, with correlation coefficients (R2) fell between 0.9920 and 0.9999. 
DON and DOM-1 displayed excellent method recoveries (RM) ranged from 80% to 112%. The inter-day and 
intra-day RSD were 3.8–12.5% and 3.2–13.3%. And no apparent carry-over was observed by injections of reagent 
blanks directly after high contaminated urine samples. A summary of validation parameters can be found in 
Table 2, all in accordance with the acceptance criteria.
Urinary DON biomarkers in the Chinese subjects. The high-throughput strategy was implemented to 
monitor the occurrence of DON biomarkers in urine samples collected from 151 healthy volunteers in Henan 
province, China. The demographic characteristics of the subjects are shown in Table 3.
Chromatograms of a human urine sample naturally contaminated with DON and DOM-1 are shown in Fig. 2. 
In the absence of the β-glucuronidase digestion step, 92.7% (n = 140/151) of samples were positive for free DON 
(fDON) and 2.0% (n = 3/151) were positive for free DOM-1 (fDOM-1). The mean level (range) of fDON was 
8.25 (<LOD-47.0) ng mL−1. Free DOM-1 was quantified in only one sample at a low level of 0.23 ng mL−1. After 
Analyte
Spiked level 
(ng mL−1)
Measured 
(ng mL−1)
Method 
recovery (%)
RSDr
LOD  
(ng mL−1)
LOQ  
(ng mL−1)
Intra-day 
(n = 6)
Inter-day 
(n = 18)
DON
2 1.9 94 12.5 13.3
0.5 110 11.2 112 3.8 3.2
50 20.8 104 7.1 8.4
DOM-1
2 1.6 80 7.3 9.5
0.1 0.210 9.1 91 6.4 4.5
50 18.2 91 4.4 6.6
Table 2. Sensitivity, accuracy and precision of the developed method.
Variables Children Adolescents Adults elderly
Number of subjects 33 14 68 36
Male 2 2 34 18
Female 31 12 34 18
Age 6 ± 3 (2–12) years 15 ± 1 (13–17) years 40 ± 13 (21–64) years 72 ± 4 (66–81) years
Weight 25 ± 10 (12–50) kg 51 ± 8 (40–64) kg 70 ± 13 (45–95) kg 65 ± 11 (46–91) kg
Table 3. Characteristics of the subjects (mean ± SD (range)).
Figure 2. Chromatograms of a naturally contaminated urine sample before (left) and after (right) 
β-glucuronidase hydrolysis (free DON, 20.4 ng mL−1; free DOM-1, <LOQ; total DON, 116.2 ng mL−1; total 
DOM-1, 6.4 ng mL−1).
www.nature.com/scientificreports/
4SCieNtiFiC REPORtS |  (2018) 8:3901  | DOI:10.1038/s41598-018-22206-y
enzymatic hydrolysis, urinary total DON (tDON) was quantified in 100% (n = 151/151) of the samples, with 
the mean value (range) of 47.6 (1.36–247) ng mL−1; and a detection rate (30.5%, n = 46/151) of total DOM-1 
(tDOM-1) was obtained, at a mean level (range) of 0.28 (<LOD-6.43) ng mL−1 (Table 4). As can be seen, glucu-
ronide conjugates are the main metabolites for both DON and DOM-1. It should also be mentioned that, DON 
acetylated derivatives (3-A-DON and 15-A-DON), known as masked DON were also measured in our study. The 
key experimental parameters were presented in Supplementary Information (Tables S2 and S3). However, neither 
of them was detected in 151 urine samples (both with and without enzyme hydrolysis), which provide further 
demonstration for the rapid digestion of 3-A-DON and 15-A-DON in vivo after ingestion.
The urinary tDON (free DON + DON-glucuronides) concentrations taken as biomarker for exposure to 
DON were further analyzed by gender and 4 age groups (0–12, 13–18, 19–65, and >65). The mean level of tDON 
was slightly higher in female (52.8 ± 56.5 ng mL−1) than in male (38.8 ± 32.2 ng mL−1), but the difference did 
not reach statistical significance (P = 0.475). All the 4 age groups were positive for DON and DOM-1. The mean 
levels of tDON were highest in children (age ≤ 12, 63.2 ± 52.6 ng mL−1) and adolescents (age 13–18, 73.1 ± 61.0 
ng mL−1), with no significant difference (P = 0.664) between them. Urinary tDON was about 1.5-fold lower in 
adults (age 19–65, 45.1 ± 44.5 ng mL−1) than in children and adolescents (P < 0.05). The elderly group (age > 65, 
27.8 ± 42.2 ng mL−1) had the lowest tDON levels (P < 0.01), as presented in Table 5.
Compound
Positive n 
(%)
Mean (±SD) 
(ng mL−1)
Median 
(ng mL−1)
Range  
(ng mL−1)
fDON 140 (92.7) 8.25 (±8.74) 5.48 ND–47.0
tDON 151 (100) 47.6 (±49.2) 32.5 1.36–247
fDOM-1 3 (2.0) 0.052 (±0.015) 0.05 ND–0.23
tDOM-1 46 (30.5) 0.28 (±0.79) 0.05 ND–6.43
Table 4. Summary of free and total DON and it’s metabolites in 151 urine samples. ND, level below LOD; 
positive samples refer to the levels higher than LOD. When calculating the mean and median values, level below 
LOQ was set to half of the LOQ, and level below LOD was set to half of the LOD.
Compound
Positive Mean (± SD) Median Range
n (%) ng mL−1 ng mL−1 ng mL−1
Gender
Male, n = 56
tDON 56 (100%) 38.8 (±32.2) 29.8 3.11–132
fDON 49 (87.5%) 5.96 (±6.03) 4.25 ND–25.2
tDOM-1 14 (25.0%) 0.37 (±1.08) 0.05 ND–6.43
Female, n = 95
tDON 95 (100%) 52.8 (±56.5) 33.4 1.36–247
fDON 91 (95.8%) 9.60 (±9.78) 6.47 ND–47.0
tDOM-1 32 (33.7%) 0.22 (±0.54) 0.05 ND–3.49
Age
Age ≤ 12, n = 33
tDON 33 (100%) 63.2 (±52.6) 44.6 7.42–224
fDON 32 (97.0%) 11.3 (±10.5) 7.79 ND–47.0
tDOM-1 12 (36.4%) 0.16 (±0.25) 0.05 ND–1.05
12 < Age ≤ 18, n = 14
tDON 14 (100%) 73.1 (±61.0) 52.4 11.4–240
fDON 14 (100%) 13.0 (±10.8) 9.85 1.00–37.4
tDOM-1 5 (35.7%) 0.11 (±0.10) 0.05 ND–0.35
18 < Age ≤ 65, n = 68
tDON 68 (100%) 45.1 (±44.5) 29.8 3.31–213
fDON 65 (95.6%) 8.05 (±7.38) 5.79 ND–31.1
tDOM-1 21 (30.9%) 0.36 (±1.03) 0.05 ND–6.43
Age > 65, n = 36
tDON 36 (100%) 27.8 (±42.2) 10.98 1.36–247
fDON 29 (80.6%) 3.96 (±6.49) 2.48 ND–37.0
tDOM-1 8 (22.2%) 0.40 (±0.74) 0.05 ND–2.91
Table 5. Urinary tDON and tDOM-1 by gender and age groups. ND, level below LOD; positive samples refer to 
the levels higher than LOD. When calculating the mean and median values, level below LOQ was set to half of 
the LOQ, and level below LOD was set to half of the LOD.
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Discussion
Urinary DON levels comparison. The present study was conducted for the residents in Henan province 
located in the central part of China, where wheat as the staple food, are consumed often at higher levels than in 
other provinces in China31. Accordingly, the average urinary concentration of tDON in the healthy subjects was 
much higher than those from Shanghai (n = 60, 97% positive, mean 4.8 ng mL−1)20 and Yunnan (n = 4, 100% 
positive, mean 12 ng mL−1) inhabitants12, and slightly higher than those of cancer patients in Henan province 
(100% positive, mean 37 ng mL−1) in 200312. This reflected regional and temporal variability of DON exposure 
in the Chinese population.
Moreover, the tDON values in this study were also higher than those reported in Bangladesh (n = 54, 52% 
positive, mean 0.86 ng mL−1; n = 62, 27% positive, mean 0.17 ng mL−1)21,22, Cameroon (n = 220, 73% positive, 
mean 2.22 ng mL−1; n = 145, 43% positive, mean 5.93 ng mL−1)32,33, Egypt (n = 93, 68% positive, mean 1.11 ng/
mg creatinine)34, Nigeria (n = 120, 5% positive, mean 3.9 ng mL−1)35, Tanzania (n = 166, 51% positive, mean 2.5 
ng mL−1)10, South Africa (n = 53, 100% positive, mean 20.4 ng/mg creatinine)36, Austria (n = 27, 59% positive, 
mean 20.4 ng mL−1)37, France (n = 67, 99% positive, 0.5–28.8 ng mL−1)38, Germany (n = 50, 100% positive, mean 
9.02 ng mL−1; n = 30, 100% positive, mean 7.15 ng mL−1; n = 101, 30% positive, mean 3.38 ng mL−1)22,39,40, Italy 
(n = 52, 96% positive, mean 11.89 ng mL−1; n = 10, 70% positive, mean 3.7 ng mL−1)41,42, Spain (n = 54, 69% 
positive, mean 23.3 ng/mg creatinine)16, Sweden (n = 29, 97% positive, mean 10.8 ng mL−1; n = 326, 90% posi-
tive, mean 2.9 ng mL−1; n = 252, 73% positive, mean 5.38 ng mL−1)43–45, U.K. (n = 15, 100% positive, mean 13.5 
ng mL−1; n = 25, 100% positive, mean 10.8 ng mL−1; n = 300, 99% positive, mean 8.9 ng/mg creatinine; n = 35, 
100% positive, mean 11.6 ng mL−1; n = 34, 68% positive, mean 2.4 ng mL−1; n = 85, 100% positive, mean 10.3 ng/
mg creatinine)6,13,46–49 and Haiti (n = 142, 17% positive, mean 3.2 ng mL−1)23. On the other hand, the determined 
tDON levels in the Chinese participants was lower than those in Belgian volunteers (n = 32, 100% positive, mean 
59.0 ng mL−1)24 and pregnant women (n = 40) from Croatia (97.5% positive, mean 111.8 ng/mL, range 4.8–1238 
ng/mg)50.
Urinary DOM-1 levels comparison. Urinary tDOM-1 after β-glucuronidase hydrolysis was reported in 
the low ng mL−1 range in several studies6,16,22,24,34,39,45,49, whereas it was not detected in other surveys37,46. In our 
study, tDOM-1 was detected in 30.5% of the samples, comparable with the prevalence of tDOM-1 in France 
(34%)38, Belgium (25%)24, Germany (40%; 50%)22,39 and UK (37% in 2012 and 40% in 2013)6, but apparently 
higher than in Sweden (8%)45, Spain (3.7%)16, Egypt (2%)34 and another study in UK (3%)49.
Considering the occurrence of tDOM-1 in several previous studies, fDOM-1 in urine can also be anticipated. 
In our study, fDOM-1 was first evidenced in human urine, which was detected in 2.0% (n = 3/151) of the sam-
ples. All the three samples were from male adults; their urinary tDON, tDOM-1 and fDOM-1 levels were 20.7 
ng mL−1, 4.07 ng mL−1 and 0.22 ng mL−1, 42.0 ng mL−1, 6.43 ng mL−1and <LOQ, 32.2 ng/ml, 2.53 ng mL−1 and 
<LOQ, respectively. It is noteworthy that the three positive samples also shared high levels of tDOM-1 (ranked 
of 1st, 2nd and 7th), whereas their tDON levels were not remarkably high (ranked 58th, 77th and 100th). It is possible 
that these participants are more likely to detoxify DON to DOM-1 than others. This is the first demonstration of 
urinary free DOM-1 in humans.
Correlation between different urinary biomarkers. Free DON levels were significantly corre-
lated with the levels of tDON (Fig. 3a, r = 0.765, P < 0.001). On average 82.7% of the tDON was present as 
DON-glucuronides, in line with the recent findings in Austria (86%) directly quantifying DON, D-3-GlcA 
and D-15-GlcA37, and in UK (91.1%) comparing DON levels before and after β-glucuronidase hydrolysis49. 
Conjugation with glucuronic acid to DON-glucuronides appears to be a major route of DON detoxification and 
excretion. These results confirm that tDON is a more important urinary biomarker than fDON in reflecting the 
dietary DON exposure.
On the contrary, no significant correlation existed between tDOM-1 and tDON (Fig. 3b, r = −0.013, 
P = 0.932) for samples with detectable tDOM-1. However, the level of tDON (75.7 ± 65.6 ng mL−1, p < 0.001) 
was higher for those samples positive for tDOM-1 compared to the samples where tDOM-1 was not detected 
Figure 3. Scatterplot of urinary fDON (a) and urinary tDOM-1 (b) against urinary tDON, all in logarithmic 
scale. Levels below LOQ were set to half of the LOQ, and levels below LOD were set to half of the LOD.
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(35.3 ± 33.7 ng mL−1). In the 46 positive samples urinary tDOM-1 represented 3.17% (range 0.05–19.6%) of the 
amount of urinary tDON. Five samples among them possessed proportions of tDOM-1 (10.5–19.6% of tDON) 
higher than 10%.
Estimated dietary DON intake. A probable daily intake (PDI) for DON could be estimated for the par-
ticipants using equation (1), based on the urinary DON biomarker levels determined in this study and a urinary 
excretion rate published before5:
=
× ×
×
C V
W E
PDI 100 (1)
where C = total DON concentration (μg L−1), V = daily urine excretion (L), W = the individual body weight of 
each participant (kg), E = excretion rate (%).
A mean daily urine excretion was assumed to be 0.5 L for children and 1.5 L for adults51,52. An excretion rate of 
68% (including 52% as DON-glucuronides and 16% as free DON)5 was used for the calculation. PDI calculated 
for DON ranged 0.038–9.62 μg/kg bw; and 79 of the 151 participants (52.3%) exceeded the PMTDI value set by 
JECFA (1 μg/kg bw/day)3. For the 4 age groups, children (2.09 ± 1.81 μg/kg bw) and adolescents (3.08 ± 2.44 μg/
kg bw) have the highest PDI, with no significant difference (P = 0.126) between them. The PDI of DON was lower 
(P < 0.05) for adults (1.41 ± 1.47 μg/kg bw) than for children and adolescents. The elderly group (0.98 ± 1.41 μg/
kg bw) had the lowest PDI (P < 0.01), as summarized in Table 6. Remarkably, the mean and median PDI for the 
entire cohort estimated to be 1.61 μg/kg bw and 1.10 μg/kg bw both exceeded the PMTDI, indicating a potential 
risk for the residents in Henan province, China. This could be partially attributed to the high consumption of 
cereals in this area.
This situation was similar for Croatia (mean 111.8 ng/mL)50 and Belgain (mean 59.0 ng mL−1)24, mean daily 
intakes being 4.1 and 2.2 μg/kg bw/d respectively, exceeding the PMTDI. Especially in Croatia, nearly half of the 
subjects were estimated to exceed the PMTDI. On the contrary, most other studies around the world reported 
acceptable mean levels of tDON ranging from 0.2 to 20 ng/mL as mentioned above, corresponding to the daily 
intakes between 0.007 and 0.74 μg/kg bw/d, below the PMTDI value of 1 μg/kg bw/d.
Methods
Chemicals and materials. Standard solutions of DON (100 μg mL−1), DOM-1 (50 μg mL−1), and 13C15-
DON (10 μg mL−1) were purchased from Biopure (Tulln, Austria). Beta-glucuronidase (Type IX from E. coli) was 
from Sigma-Aldrich (MO, USA). LC-MS grade water, acetonitrile, methanol, formic acid and ammonia acetate 
were supplied by Fisher Scientific (Leicestershire, United Kingdom). All other chemicals and reagents used were 
of analytical grade or better. The Oasis PRiME HLB 96-well μElution plate (3 mg/30 μm) was product of Waters 
(Milford, MA, USA). A mixed standard containing 10 μg mL−1 of each analyte was prepared in ACN/H2O (50/50, 
v/v) and stored at 4 °C. Working dilutions of mixed standards were freshly prepared for each run in methanol/
H2O (20/80). The enzyme solution containing 2000 U mL−1 β-glucuronidase was prepared in phosphate buffer 
(0.075 mol L−1, pH 6.8) freshly on each day of use.
Sample collection and storage. Urine samples of 151 healthy volunteers aged 2–78 years (56 males, 95 
females) were collected in Henan province located in the middle of China. For each person, morning urine sam-
ples were collected on three consecutive days, immediately frozen stored at −70 °C. The urine from the three days 
were mixed at a 1:1:1 ratio to make one sample prior to DON biomarker analyses. The study was approved by the 
ethics committee of China National Center for Food Safety Risk Assessment, and all the methods were performed 
according to the approved guidelines and regulations. All the participants were completely informed of the pur-
pose of this study, and the informed consents from the adult participants or parents on behalf of their children 
who participated the study were obtained.
Preparation of calibration standards and quality control samples. Serial calibration standard solu-
tions at levels of 1, 2, 5, 10, 20, 50 and 100 ng mL−1 for each analytes were prepared by dilutions of the mixed 
standard solution (20 μg mL−1 of each compound). Each calibration standard solution contained 10 ng mL−1 of 
13C15-DON as internal standard, which was used for quantification of DON. Quality control (QC) samples at levels 
of 2, 10 and 50 ng mL−1 were prepared by spiking analyte-free urine with mixed standard solutions. The QC samples 
were included in each batch of 80 samples, and their measured values should be within ±15% of the nominal values.
Age
Mean 
(± SD) Median Range
Exceeding 
PMTDI
μg/kg bw μg/kg bw μg/kg bw n (%)
Age ≤ 12, n = 33 2.09 (±1.81) 1.47 0.23–7.57 23 (69.7%)
12 < Age ≤ 18, n = 14 3.08 (±2.44) 2.28 0.58–9.62 12 (85.7%)
18 < Age ≤ 65, n = 68 1.41 (±1.47) 0.99 0.12–9.26 34 (50%)
Age > 65, n = 36 0.98 (±1.41) 0.54 0.038–7.79 10 (27.8%)
Total, n = 151 1.61 (±1.73) 1.10 0.038–9.62 79 (52.3%)
Table 6. PDI of DON by 4 age groups. When calculating the PDI, level below LOQ was set to half of the LOQ, 
and level below LOD was set to half of the LOD.
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Sample preparation. Urine samples were thawed and centrifuged at 5000 × g for 15 min. Internal standard, 
13C15-DON, was added to 1 mL supernatant at a final concentration of 10 ng mL−1, followed by a 2.5-fold dilution 
with phosphate buffer (75 mM, pH 6.8). A portion of 500 μL diluted sample was cleaned via Oasis® PRiME HLB 
μElution Plate (pre-conditioned with 200 μL methanol and 200 μL of water). After the loaded samples were slowly 
passed through under vacuum, the wells were washed with 200 μL of water to remove interference from urine 
matrix. Then the analytes were eluted twice with 100 μL each of methanol and diluted with 800 μL of water before 
the LC-MS/MS analysis. For the measurement of total DON and DOM-1, an enzyme digestion was added. 1 mL 
of the urine sample were first mixed with 1.5 mL phosphate buffer (75 mM, pH 6.8) containing 2000 Units of 
β-glucuronidase and incubated in a shaking water-bath at 37 °C for 18 h for digestion before the centrifugation.
LC-MS/MS analysis. Analysis was performed on an ACQUITY UPLC™ I-Class system (Waters, MA, 
USA) connected to a Xevo® TQ-S tandem quadrupole mass spectrometer (Waters, MA, USA) equipped with 
an electrospray ionization (ESI) source. Chromatographic separation of DON biomarkers was achieved on a 
CORTECS™ UPLC® C18 Column (2.1 × 100 mm, 1.6 μm, Waters, MA, USA). The mobile phase consisted of 
solvent A (water) and solvent B (methanol/acetonitrile, 80/20, v/v), running a gradient program as follow: 10% 
B at 0–1.5 min, 10–20% B at 1.5–1.8 min, 20% B at 1.8–7 min, 90% B at 7.1–8 min and 10% B at 8.1–9 min. The 
total run time was 9 min and the flow rate was set at 0.4 mL/min. The injection volume was 10 μL and the column 
temperature was maintained at 40 °C. MS/MS analysis in multiple reaction monitoring mode (MRM) was used 
to quantify DON biomarkers by reference to internal standard. Ion spray voltage was set to 3.0 kV in positive 
ionization mode. The MRM transitions, collision energies and cone voltages were optimized for each analyte as 
presented in Table 1. Other parameters were: source temperature, 150 °C; desolvation gas, nitrogen, 900 L h−1, 
500 °C; cone gas, nitrogen, 150 L h−1; collision gas, argon, 0.15 mL/min.
Method validation. Validation in terms of linearity, specificity, accuracy, precision (intra and inter-day 
variability) and sensitivity (LOD and LOQ) were evaluated for DON biomarkers according to the guidelines 
defined by the European Medicines Agency (EMEA)29 and US Food and Drugs Administration (FDA)30. The 
LOD (S/N = 3) and LOQ (S/N = 10) of the assay were determined using spiked urine samples at low levels. The 
linearity was assessed from a calibration curve on three consecutive days, using linear regression with 1/x weight-
ing. The accuracy, expressed as the method recoveries (RM), as well as inter-day and intra-day precision were 
investigated at low (2 ng mL−1), medium (10 ng mL−1) and high (50 ng mL−1) spiking levels in blank urine in six 
replicates with internal standards correction.
Statistical analysis. For statistical tests, undetectable DON biomarker concentration was set as half the 
value of their respective LOD51,53. The concentration data of DON biomarkers was natural log transformed for 
normality, prior to analyses with independent sample t-test and ANOVA to determine the differences in urinary 
DON levels of different subgroups (age, gender). The concentration of total DOM-1 was non-normally distrib-
uted even after logarithmically transformation. As a result, Pearson and Spearman tests were used separately to 
assess the correlations between total DON with free DON and total DOM-1. Statistical analysis was performed 
using SPSS, version 19 (SPSS, Chicago, IL, USA). A p-value <0.05 was considered as statistically significant.
Data availability. The datasets generated during and/or analysed during the current study are available from 
the corresponding author on reasonable request.
Conclusions
A high-throughput LC-MS/MS method was tested for the first time for urinary DON and DOM-1 analysis. The 
involvement of a 96-well μElution plate allowed the simultaneous preparation of 96 samples within 2 h, without 
the requirement of evaporation and reconstitution steps. The method, with significantly improved efficiency and 
accuracy, provides a powerful tool for large-scale population studies. With this method DON, and DOM-1 to a 
lesser extent, can be frequently detected in the Chinese urine samples both with and without enzyme hydroly-
sis. Free DOM-1 was detected at low level in a small fraction of human urine for the first time. Total DON was 
detected in all samples with a mean concentration at 47.6 ng mL−1, higher than most populations previously 
studied. The PDI of children and adolescents estimated based on the biomarkers levels, were higher than the 
adults and elders. Over 50% of the population in study exceeded the PMTDI set by JECFA, indicating a potential 
health risk from DON exposure.
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